WCLC24: Rybrevant-Lazcluze Combination Shows Enhanced Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC

Survival Benefit:
The Rybrevant-Lazcluze combination demonstrated a 23% overall survival (OS) benefit over Tagrisso, with 61% of patients on the combo regimen alive at three years compared to 53% on Tagrisso monotherapy.

Intracranial Progression-Free Survival:
The combination showed a significant improvement in intracranial progression-free survival, with 38% of patients on the combo regimen versus 18% on Tagrisso.

First-Line Treatment:
The Rybrevant-Lazcluze combination is approved for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

MARIPOSA Study:
The Phase III MARIPOSA study supported the approval, showing that the combination reduced the risk of disease progression or death by 30% versus Tagrisso, with a nine-month-longer median duration of response.

Chemotherapy-Free Regimen:
The Rybrevant-Lazcluze combination is the first and only chemotherapy-free regimen showing superior progression-free survival versus osimertinib (Tagrisso).